Verona Pharma (VRNA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The strong price relationship between silver and copper is likely reinforced and amplified by trading algorithms that ...

Corteva offers defensive play for stagflation with strong performance and diversification, making it a buy for commodity ...

Following a brief spell in the positive, benchmark indices Nifty and Sensex erased gains to trade in the red after a sharp ...

The S&P/ASX 200 closed 35.1 points lower, down 0.42%. For the most part, Aussie investors chose the sidelines today ahead of ...

NZD/USD finds a temporary cushion near the two-year low of 0.5520 on a weekly timeframe. However, the outlook for the Kiwi ...

The broader market is divided into 11 sectors and overall it had a great year in 2024, managing a 25% total return. Much of ...

On the surface it looked like a quiet day on the benchmark S&P/ASX 200, a modest 0.24% fall...but this was around half a ...

Newcastle United striker Alexander Isak is a reference point for talents in Sweden, where he grew up, and Eritrea, where his ...

PRNewswire/ - Sandstorm Gold Ltd. ("Sandstorm Gold Royalties", "Sandstorm", or the "Company") (NYSE: SAND) (TSX: SSL) is pleased to ...

Natural Resource Partners is a riskier investment due to commodity cycles, but improvements in debt and valuation make it ...

Resources stocks rebounded today, leading the S&P/ASX 200 to its fifth consecutive gain. That's 5 out of 5 for 2025. That has ...